Serpatinib (Retevmo), as a highly selective RET inhibitor, has shown significant efficacy in the treatment of RET gene mutant tumors. At the same time, attention should be paid to its interaction and storage with CYP3A4 related drugs and food.

therapeutic effect

1. RET fusion positive non-small cell lung cancer: Objective response rate (ORR) reached 64%, median progression free survival (mPFS) was 16.5 months, and intracranial lesion control rate was 91%.

2. Medullary thyroid carcinoma: The ORR of previously treated patients is 69%, while the ORR of newly treated patients is 73%, with a median progression free survival of 23.6 months.

3. Patients with brain metastases: The intracranial ORR is 85%, and the median intracranial PFS is 13.7 months, which is significantly better than traditional treatment options.

Drug interactions

1. CYP3A4 inhibitors: Strong CYP3A4 inhibitors may increase the blood concentration of Serpatinib, and it is necessary to avoid using foods such as grapefruit and Seville orange at the same time.

2. CYP3A4 inducers: May reduce the efficacy of Selpatinib, and long-term combination use of drugs such as rifampicin should be avoided.

3. P-gp inhibitors: may increase the plasma concentration of Serpatinib, and drug toxicity needs to be monitored for an increase.

4. Gastric acid regulating drugs: Proton pump inhibitors and other drugs may reduce the bioavailability of Serpatinib, and it is recommended to administer them intermittently.

5. Medications for QT interval prolongation: may have a cumulative effect and require regular monitoring of electrocardiogram and electrolytes.

Standard storage conditions

1. Temperature control: It should be stored in a room temperature environment of 20 ° C to 25 ° C (68 ° F to 77 ° F), allowing short-term fluctuations to 15 ° C to 30 ° C (59 ° F to 86 ° F).

2. Original packaging preservation: Tablets/capsules should be kept in their original packaging containers to ensure sealing and prevent moisture.

Special precautions

1. Avoid extreme temperatures: Freezing or refrigerating is strictly prohibited, as temperatures exceeding 30 ° C may cause drug degradation.

2. Humidity control: The relative humidity of the storage environment should be below 75%, and it is recommended to place desiccants.